MA49566A - Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques - Google Patents
Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiquesInfo
- Publication number
- MA49566A MA49566A MA049566A MA49566A MA49566A MA 49566 A MA49566 A MA 49566A MA 049566 A MA049566 A MA 049566A MA 49566 A MA49566 A MA 49566A MA 49566 A MA49566 A MA 49566A
- Authority
- MA
- Morocco
- Prior art keywords
- sodium channel
- channel inhibitors
- carboxamides used
- carboxamides
- inhibitors
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531313P | 2017-07-11 | 2017-07-11 | |
| US201762608283P | 2017-12-20 | 2017-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49566A true MA49566A (fr) | 2020-05-20 |
Family
ID=63036498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049566A MA49566A (fr) | 2017-07-11 | 2018-07-11 | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10647661B2 (fr) |
| EP (1) | EP3651752B1 (fr) |
| JP (1) | JP7277431B2 (fr) |
| KR (1) | KR20200026987A (fr) |
| CN (1) | CN111065383A (fr) |
| AU (1) | AU2018300150A1 (fr) |
| BR (1) | BR112020000553A2 (fr) |
| CA (1) | CA3069720A1 (fr) |
| CL (1) | CL2020000075A1 (fr) |
| CO (1) | CO2020000145A2 (fr) |
| CR (1) | CR20200064A (fr) |
| DO (1) | DOP2020000004A (fr) |
| EC (1) | ECSP20003147A (fr) |
| ES (1) | ES3008911T3 (fr) |
| IL (1) | IL271948A (fr) |
| JO (1) | JOP20200001A1 (fr) |
| MA (1) | MA49566A (fr) |
| PE (1) | PE20201164A1 (fr) |
| PH (1) | PH12020500066A1 (fr) |
| SG (1) | SG11202000230VA (fr) |
| TN (1) | TN2020000001A1 (fr) |
| TW (1) | TW201920081A (fr) |
| UY (1) | UY37806A (fr) |
| WO (1) | WO2019014352A1 (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ナトリウムチャネルの調節剤としてのスルホンアミド |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| KR102714561B1 (ko) | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| RS64018B1 (sr) | 2018-02-15 | 2023-03-31 | Vertex Pharma | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| SG11202100130QA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
| GEAP202315648A (en) * | 2018-11-02 | 2023-07-25 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020146682A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides utilisés en tant que modulateurs de canaux sodiques |
| WO2020146612A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters et carbamates utilisés en tant que modulateurs de canaux sodiques |
| WO2020151728A1 (fr) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | Derive de 2-oxo-1,2-dihydropyridine, son procede de preparation et ses applications medicales |
| WO2020176763A1 (fr) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| WO2020219867A1 (fr) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
| KR20220101606A (ko) * | 2019-09-12 | 2022-07-19 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 피리딘 산질화물 및 이의 제조 방법과 용도 |
| CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| CN110937994B (zh) * | 2019-12-10 | 2022-04-22 | 浙江大洋生物科技集团股份有限公司 | 二步氯化法合成2,4-二氯-6-氟苯甲酰氯的方法 |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| JP7822960B2 (ja) | 2020-05-06 | 2026-03-03 | バイエル、アクチエンゲゼルシャフト | 殺真菌性化合物としてのピリジン(チオ)アミド |
| CN115605462B (zh) | 2020-05-12 | 2026-04-14 | 拜耳公司 | 作为杀真菌化合物的三嗪和嘧啶(硫代)酰胺 |
| EP4161914A1 (fr) * | 2020-06-04 | 2023-04-12 | Bayer Aktiengesellschaft | Pyridines hétérocyclyles en tant que nouveaux fongicides |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| KR20230026404A (ko) | 2020-06-17 | 2023-02-24 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2022036060A1 (fr) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
| CN111920796A (zh) * | 2020-08-28 | 2020-11-13 | 南京医科大学 | 化合物在制备治疗癫痫药物中的应用 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
| JP2024509939A (ja) * | 2021-03-11 | 2024-03-05 | シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド | ピリジン窒素酸化物の結晶形態およびその使用 |
| EP4320125A1 (fr) | 2021-04-05 | 2024-02-14 | Bristol-Myers Squibb Company | Composés d'oxoisoindoline à substitution pyridinyle pour le traitement du cancer |
| EP4334293A1 (fr) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopipérazine carboxamides et cyclohétéroalkyle 3-oxopipérazine carboxamides en tant qu'inhibiteurs de nav1.8 |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202600064T1 (it) * | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CA3221939A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques |
| IL308934A (en) * | 2021-06-04 | 2024-01-01 | Vertex Pharma | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| WO2022256842A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| AU2022349463A1 (en) * | 2021-09-24 | 2024-03-14 | Xenon Pharmaceuticals Inc. | Pyridinyl derivatives as sodium channel activators |
| JP2025504498A (ja) | 2022-01-18 | 2025-02-12 | 成都康弘薬業集団股分有限公司 | 芳香族縮合環nav1.8阻害剤、及びその使用 |
| CN114288289A (zh) * | 2022-02-17 | 2022-04-08 | 昆山彭济凯丰生物科技有限公司 | 具有镇痛和/或止痒功能的药物组合物及其应用 |
| CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256486A1 (fr) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur |
| CN116947713B (zh) * | 2022-04-25 | 2026-03-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| EP4534529A4 (fr) * | 2022-06-02 | 2026-06-03 | Shanghai Jemincare Pharmaceuticals Co Ltd | Procédé de préparation d'un composé d'oxynitrure de pyridine |
| TW202413335A (zh) * | 2022-06-22 | 2024-04-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Nav1.8抑制劑 |
| CN119585260A (zh) * | 2022-08-24 | 2025-03-07 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| JP2025529931A (ja) * | 2022-08-28 | 2025-09-09 | シャンハイ ホイルン ファーマシューティカル カンパニー リミテッド | ナトリウムチャネル調節剤及びその応用 |
| WO2024046409A1 (fr) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | Composé hétérocyclique, son procédé de préparation et son utilisation pharmaceutique |
| WO2024054622A2 (fr) * | 2022-09-09 | 2024-03-14 | Latigo Biotherapeutics, Inc. | Composés bloquant les canaux sodiques, leurs dérivés et leurs procédés d'utilisation |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| EP4647430A4 (fr) * | 2023-01-06 | 2026-03-11 | Haisco Pharmaceutical Group Co Ltd | Dérivé de tétrahydrothiophène et son utilisation en médecine |
| TW202434235A (zh) * | 2023-01-18 | 2024-09-01 | 芬蘭商奧利安公司 | 3-(4,5-二氯-2-(4-(三氟甲氧基)苯氧基)苯甲醯胺基)吡啶1-氧化物的製備方法 |
| PY2404093A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits |
| PY2404641A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| WO2024159287A1 (fr) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hydoxymates inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| WO2024159285A1 (fr) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Composés aryle pyridines inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| WO2024217344A1 (fr) * | 2023-04-19 | 2024-10-24 | 中国科学院上海药物研究所 | Inhibiteurs de nav1.8, leur procédé de préparation et leur utilisation |
| CN121419965A (zh) * | 2023-06-14 | 2026-01-27 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物的盐型、共晶及其制备方法和应用 |
| CN119371405A (zh) | 2023-07-26 | 2025-01-28 | 上海闻耐医药科技有限公司 | 多取代吡咯烷类衍生物、其制备方法及用途 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| WO2025124502A1 (fr) * | 2023-12-13 | 2025-06-19 | 武汉人福创新药物研发中心有限公司 | Composé inhibiteur de nav1.8, sel de celui-ci, polymorphe de celui-ci et son utilisation |
| CN120192286A (zh) * | 2023-12-21 | 2025-06-24 | 武汉熙瑞医药科技有限公司 | 一种含苯环的多环化合物、其药物组合物及其应用 |
| AU2025211735A1 (en) | 2024-01-24 | 2026-07-16 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| CN118772124A (zh) * | 2024-07-01 | 2024-10-15 | 山东福长药业有限公司 | 一种Suzetrigine的制备方法 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (fr) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur |
Family Cites Families (249)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1025305A (en) | 1910-07-29 | 1912-05-07 | Andrew Rasmussen | Feeding means for power hacksaw-machines. |
| US1008714A (en) | 1910-12-27 | 1911-11-14 | Henry M Hammer | Delinting-machine. |
| US2511231A (en) | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
| US2688617A (en) | 1951-07-17 | 1954-09-07 | American Cyanamid Co | Sulfonated dihalogeno diaminostilbenes |
| BE516025A (fr) | 1951-12-05 | |||
| US2657134A (en) | 1951-12-05 | 1953-10-27 | Eastman Kodak Co | Photographic emulsion with colored couplers containing isophthalic ester groups |
| US2725292A (en) | 1952-05-15 | 1955-11-29 | Eastman Kodak Co | Colored couplers containing solubilizing groups |
| US2710802A (en) | 1953-03-16 | 1955-06-14 | Eastman Kodak Co | Dialkyl-5-(oxanilamido) isophthalate couplers for color photography |
| US2710803A (en) | 1953-03-26 | 1955-06-14 | Eastman Kodak Co | Color couplers containing hydroxyalkyl groups |
| BE528163A (fr) | 1953-04-17 | |||
| BE531589A (fr) | 1953-09-02 | |||
| US4218765A (en) | 1974-10-03 | 1980-08-19 | Standard Oil Company (Indiana) | Two-dimensional frequency domain filtering |
| DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
| US4639273A (en) | 1983-05-06 | 1987-01-27 | Morton Thiokol, Inc. | Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines |
| JPS63182182A (ja) | 1987-01-23 | 1988-07-27 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| FR2628864B1 (fr) | 1988-03-21 | 1990-06-15 | France Etat | Procede de segmentation d'un champ de vecteurs vitesse, notamment de vitesses de deplacement de points d'une image dans une sequence d'images |
| AU6062590A (en) | 1989-07-07 | 1991-02-06 | Schering Corporation | Pharmaceutically active compounds |
| JP2766323B2 (ja) | 1989-07-19 | 1998-06-18 | 株式会社東芝 | 表示調整装置 |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| DE4019307A1 (de) | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
| US5449691A (en) | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
| US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
| JPH05313169A (ja) | 1992-05-08 | 1993-11-26 | Fuji Photo Film Co Ltd | 液晶配向膜 |
| HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| GB9408185D0 (en) | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
| CN1048239C (zh) | 1994-05-31 | 2000-01-12 | 帝人株式会社 | 萘衍生物 |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5536718A (en) | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
| US5532235A (en) | 1995-01-17 | 1996-07-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19523640A1 (de) | 1995-06-29 | 1997-01-02 | Bayer Ag | Substituierte Carbonylaminophenyluracile |
| DE19621522A1 (de) | 1996-05-29 | 1997-12-04 | Hoechst Schering Agrevo Gmbh | Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung |
| JP3731963B2 (ja) | 1997-01-14 | 2006-01-05 | 株式会社シマノ | 釣り竿用口栓 |
| JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
| TR199902593T2 (xx) | 1997-04-22 | 2000-03-21 | Neurosearch A/S | �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�. |
| WO1999047529A1 (fr) | 1998-03-18 | 1999-09-23 | Ariad Pharmaceuticals, Inc. | Inhibiteurs de transduction de signaux heterocycliques et compositions les contenant |
| EP1076641A1 (fr) | 1998-04-29 | 2001-02-21 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de l'enzyme impdh |
| JP2002179651A (ja) | 1998-06-19 | 2002-06-26 | Wakamoto Pharmaceut Co Ltd | ベンズアニリド誘導体及び医薬組成物 |
| EP1514867A3 (fr) | 1998-10-22 | 2005-03-23 | NeuroSearch A/S | Dérivés de phényle substitués, leur préparation et utilisation |
| NZ515087A (en) | 1999-04-28 | 2003-11-28 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
| AU6228000A (en) | 1999-07-23 | 2001-02-13 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
| WO2001064642A2 (fr) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides et inhibiteurs connexes du facteur xa |
| MXPA02007603A (es) | 2000-03-09 | 2003-02-24 | Aventis Pharma Gmbh | Usos terapeuticos de mediadores ppar. |
| MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| NZ525591A (en) | 2000-10-05 | 2004-04-30 | Fujisawa Pharmaceutical Co | Benzamide compounds as Apo B secretion inhibitors |
| CA2426430C (fr) | 2000-10-20 | 2014-10-07 | Biocryst Pharmaceuticals, Inc. | Composes biaryle utilises comme inhibiteurs de serine protease |
| EP1332131A2 (fr) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Derives d'acide utiles comme inhibiteurs de serines proteases |
| US7056910B2 (en) | 2000-11-28 | 2006-06-06 | Astellas Pharma Inc. | 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
| PT1345900E (pt) | 2000-12-06 | 2007-03-30 | Sanofi Aventis Deutschland | Derivados amidina e guanidina como inibidores do factor xa |
| CN1289072C (zh) | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
| EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
| WO2002054077A2 (fr) | 2000-12-29 | 2002-07-11 | 7Tm Pharma A/S | Validation de molecules biologiques en tant que cibles de medicaments au moyen de chelates d'ions metalliques chez des modeles d'animaux de laboratoire |
| AU2002254107B2 (en) | 2001-03-05 | 2006-12-21 | E. I. Du Pont De Nemours And Company | Heterocyclic diamide invertebrate pest control agents |
| DE60139510D1 (de) | 2001-04-06 | 2009-09-17 | Biocryst Pharm Inc | Biarylverbindungen als serinproteaseinhibitoren |
| WO2002090347A1 (fr) | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Composes biarylcarboxamide comme inhibiteurs d'apolipoproteine b |
| WO2002098839A1 (fr) | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides et procede de preparation de ceux-ci |
| AU2002312370A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Antipathogenic benzamide compounds |
| WO2003003009A1 (fr) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Utilisation de chelates a ions metalliques dans la validation de molecules biologiques utilisees comme cibles medicamenteuses dans des modeles animaux experimentaux |
| WO2003003008A1 (fr) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments |
| DE10132686A1 (de) | 2001-07-05 | 2003-01-16 | Boehringer Ingelheim Pharma | Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2003013516A1 (fr) | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Composes servant a moduler l'accumulation des graisses |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| WO2003045921A1 (fr) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Composes d'amide heterocycliques en tant qu'inhibiteurs de l'apolipoproteine b |
| AU2002367087A1 (en) | 2001-12-21 | 2003-07-15 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
| CA2471566A1 (fr) | 2002-01-10 | 2003-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combinaison d'inhibiteurs de mtp ou d'inhibiteurs de secretions apob avec des fibrates en vue d'une utilisation comme medicament |
| JP2005516037A (ja) | 2002-01-22 | 2005-06-02 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | ジアミド無脊椎有害生物防除剤 |
| ZA200502496B (en) | 2002-02-28 | 2005-10-12 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
| CN1652759A (zh) | 2002-03-11 | 2005-08-10 | 泰博特克药品有限公司 | 小分子进入抑制剂 |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| JP2004043456A (ja) | 2002-05-24 | 2004-02-12 | Yamanouchi Pharmaceut Co Ltd | ベンゾアゼピン誘導体又はその塩を有効成分とする医薬 |
| JP2003342175A (ja) | 2002-05-24 | 2003-12-03 | Yamanouchi Pharmaceut Co Ltd | 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤 |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| JP2004175739A (ja) | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| MX271169B (es) | 2002-12-12 | 2009-10-23 | Ciba Sc Holding Ag | Derivados de hidroxifenil-benzofenona sustituidos con amino. |
| WO2004056777A1 (fr) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Inhibiteurs de proteine microsomale de transfert de triglyceride |
| ES2387803T3 (es) | 2003-01-08 | 2012-10-02 | Novartis Vaccines And Diagnostics, Inc. | Agentes antibacterianos |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| JP2004315395A (ja) | 2003-04-14 | 2004-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な安息香酸誘導体又はその塩 |
| WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
| JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| ES2619203T3 (es) | 2004-01-28 | 2017-06-23 | Mitsui Chemicals Agro, Inc. | Derivados de amida, procesos para la producción de los mismos y método para su aplicación como insecticidas |
| DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| US7427390B2 (en) | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
| WO2006007864A1 (fr) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Traitement d'etats neurodegeneratifs |
| WO2006011050A2 (fr) | 2004-07-23 | 2006-02-02 | Pfizer Limited | Derives de pyridine |
| DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| WO2006068199A1 (fr) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | Dérivés de 3-oxy-1,2,4-triazole métaboliquement stables |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| BRPI0611596A2 (pt) | 2005-06-21 | 2010-09-21 | Mitsui Chemicals Inc | derivado de amina e inseticida contendo o mesmo |
| ES2400371T3 (es) | 2005-07-07 | 2013-04-09 | Abbott Laboratories | Promotores de la apoptosis |
| JP4580836B2 (ja) | 2005-07-25 | 2010-11-17 | 三井化学アグロ株式会社 | 殺虫殺菌組成物 |
| CA2621406A1 (fr) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Composes actifs sur les ppar |
| EP1942732A2 (fr) | 2005-11-02 | 2008-07-16 | Cytokinetics, Inc. | Entites et compositions chimiques et methodes associees |
| WO2007052843A1 (fr) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Compose amide heterocyclique et son utilisation |
| WO2007071632A2 (fr) | 2005-12-20 | 2007-06-28 | Neurosearch A/S | Derives de pyridinyl-quinazoline et leur utilisation medicale |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| EP2073806B1 (fr) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Utilisation de composés de spiro-oxindole comme agents thérapeutiques |
| US20090325956A1 (en) | 2006-10-13 | 2009-12-31 | Takahiko Taniguchi | Aromatic amine derivative and use thereof |
| JP2008106017A (ja) | 2006-10-27 | 2008-05-08 | Tokyo Univ Of Science | Oatp選択的阻害性を有する化合物、及び該化合物を含むoatpの選択的阻害剤 |
| PT2101760E (pt) | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP4325681B2 (ja) | 2007-02-13 | 2009-09-02 | ソニー株式会社 | 固体撮像装置、撮像装置 |
| WO2008104994A2 (fr) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | Dérivés d'acétamide 2,2,2-tri-substitué en tant qu'activateurs de la glucokinase, leur procédé de préparation et leur application pharmaceutique |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| WO2008140810A1 (fr) | 2007-05-11 | 2008-11-20 | Cytokinetics, Incorporated | Certaines entités chimiques, compositions et procédés |
| JP2010531304A (ja) | 2007-06-18 | 2010-09-24 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド | 抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー |
| WO2009000413A1 (fr) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | Synthèse régiosélective catalysée par le cuivre de benzimidazoles et d'azabenzimidazoles |
| US20090012091A1 (en) | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
| CN101952248B (zh) | 2007-10-10 | 2014-04-16 | 巴斯夫欧洲公司 | 锍盐引发剂 |
| US8652752B2 (en) | 2007-10-10 | 2014-02-18 | Basf Se | Sulphonium salt initiators |
| EP2212290B1 (fr) * | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage |
| CA2701946A1 (fr) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides d'heteroaryle utilises comme inhibiteurs de canaux sodiques sensibles a une difference de potentiel |
| MX2010003864A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
| WO2009070533A1 (fr) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Procédés d'inhibition de stéaroyle-coa désaturase |
| JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
| US20100009970A1 (en) | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
| JP2010001284A (ja) | 2008-05-20 | 2010-01-07 | Sumitomo Chemical Co Ltd | 化合物及び光学フィルム |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| CN102203067B (zh) | 2008-08-25 | 2014-01-15 | Irm责任有限公司 | Hedgehog通路调节剂 |
| JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
| JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CA2734363C (fr) | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Pyrrolidine-2-carboxamides substitues |
| WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
| JP5649779B2 (ja) | 2008-11-28 | 2015-01-07 | 住友化学株式会社 | 液晶性組成物及び光学フィルム |
| MX2011006904A (es) | 2008-12-26 | 2011-07-20 | Dainippon Sumitomo Pharma Co | Compuesto heterociclico biciclico novedoso. |
| JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
| KR101641385B1 (ko) | 2009-03-16 | 2016-07-20 | 스미또모 가가꾸 가부시끼가이샤 | 화합물, 광학 필름 및 광학 필름의 제조 방법 |
| SG175711A1 (en) | 2009-05-18 | 2011-12-29 | Orion Corp | Protease inhibitors |
| EP2253617A1 (fr) | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Composés halogénés comme pesticides |
| WO2010138901A1 (fr) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés |
| JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| CA2771472A1 (fr) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Derives d'oxopiperazine pour le traitement de la douleur et de l'epilepsie |
| US20120189670A1 (en) | 2009-09-14 | 2012-07-26 | Kirkpatrick D Lynn | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
| US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
| JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
| CA2791738C (fr) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Composes d'aryl imidazolyl destines au traitement du cancer |
| EP2560636A4 (fr) | 2010-04-23 | 2013-11-27 | Kineta Inc | Composés antiviraux |
| EP2563759B1 (fr) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| WO2012016133A2 (fr) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 |
| CA2808841A1 (fr) | 2010-08-24 | 2012-03-01 | Brigham Young University | Composes antimetastatiques |
| WO2012026931A1 (fr) | 2010-08-25 | 2012-03-01 | Synta Pharmaceuticals Corp. | Procédé de synthèse de 2-alkylphénols substitués |
| EP2651405A2 (fr) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 (ck1 ) |
| KR101923367B1 (ko) | 2011-02-02 | 2018-12-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드 |
| WO2012112743A1 (fr) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocyclique chromanique en tant que modulateurs des canaux ioniques |
| CA2828456C (fr) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs n-benzyl-amino-carboxamide du canal sodique |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
| JP6007417B2 (ja) | 2011-05-31 | 2016-10-12 | レセプトス エルエルシー | 新規glp−1受容体安定剤および調節剤 |
| US20140113934A1 (en) | 2011-06-20 | 2014-04-24 | E I Du Pont De Nemours And Company | Heterocyclic compounds for treating helminth infections |
| JP2014527036A (ja) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | 癌および自己免疫疾患の処置のための方法および組成物 |
| US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| CN103012397B (zh) | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
| BR112014009102A2 (pt) | 2011-10-26 | 2017-04-18 | Pfizer Ltd | compostos químicos |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2013086229A1 (fr) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
| EP2606726A1 (fr) | 2011-12-21 | 2013-06-26 | Bayer CropScience AG | Dérivés de trifluoroéthylsulfure substitués par du N-arylamidine en tant qu'acaricides et insecticides |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| WO2013109521A1 (fr) | 2012-01-16 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocycliques pyranes utilisés en tant que modulateurs de canaux ioniques |
| WO2013114250A1 (fr) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Dérivés d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium |
| WO2013131018A1 (fr) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
| US8481479B1 (en) | 2012-03-07 | 2013-07-09 | Shaker A. Mousa | Formulations of factor VIIa inhibitors and utility |
| US8980823B2 (en) | 2012-03-07 | 2015-03-17 | Shaker A. Mousa | Formulations of Factor VIIa inhibitors and utility |
| WO2014041125A1 (fr) | 2012-09-13 | 2014-03-20 | Baden-Württemberg Stiftung Gmbh | Inhibiteurs spécifiques de la protéine p21 comme agents thérapeutiques |
| WO2014055634A1 (fr) | 2012-10-02 | 2014-04-10 | Yale University | Identification de petites molécules inhibitrices d'histone déméthylase à de domaine jumonji 1a (jarid1a) et 1b (jarid1b) interactif riche en at, |
| WO2014055644A2 (fr) | 2012-10-02 | 2014-04-10 | New York University | Compositions pharmaceutique et traitement de maladies génétiques associées à une désintégration d'arn à médiation non-sens |
| US20140200215A1 (en) | 2013-01-15 | 2014-07-17 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| BR112015018284B1 (pt) | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| CN103961348B (zh) | 2013-02-05 | 2016-08-17 | 上海交通大学医学院 | Senp1小分子抑制剂及其应用 |
| US9580400B2 (en) | 2013-02-26 | 2017-02-28 | Northeastern University | Cannabinergic nitrate esters and related analogs |
| WO2014149207A2 (fr) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Compositions insecticides à base de benzimidazole et procédés apparentés |
| JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| JP6387960B2 (ja) | 2013-05-31 | 2018-09-12 | コニカミノルタ株式会社 | 樹脂組成物、光学部材、光学フィルム、偏光板、円偏光板及び画像表示装置 |
| WO2015030898A2 (fr) | 2013-06-07 | 2015-03-05 | The Regents Of The University Of California | Commutateurs résonants micromécaniques et pompes de charge |
| WO2014204831A1 (fr) | 2013-06-18 | 2014-12-24 | Merck Sharp & Dohme Corp. | Dérivés de nucléosides cycliques à substitution phosphonate et leurs méthodes d'utilisation pour le traitement de maladies virales |
| CA2917767C (fr) | 2013-07-12 | 2022-05-03 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Cystobactamides |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ナトリウムチャネルの調節剤としてのスルホンアミド |
| CA2918534A1 (fr) | 2013-07-25 | 2015-01-29 | Fondazione Telethon | Inhibiteurs de fapp2 et leurs utilisations |
| EP3027590A1 (fr) | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hétéro)arylamides et sulfonamides, procédés permettant leur préparation et utilisations thérapeutiques de ceux-ci |
| KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
| WO2015085238A1 (fr) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibiteurs de lpxc |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US9204150B2 (en) | 2014-02-26 | 2015-12-01 | Intel Corporation | Techniques for evaluating compressed motion video quality |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2016022626A1 (fr) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antagonistes hétérocycliques des récepteurs cgrp |
| WO2016040449A1 (fr) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations |
| EP2997966A1 (fr) | 2014-09-16 | 2016-03-23 | Sanofi | Dérivés de pyrrolidine sulfonamide naphtyle en tant que modulateurs KEAP-1 pour le traitement du diabète, l'obésité, de la dyslipidémie et de troubles apparentés |
| CN106317027A (zh) | 2015-06-15 | 2017-01-11 | 山东轩竹医药科技有限公司 | 杂芳基酰胺类衍生物及其作为tgr5激动剂的应用 |
| WO2017040982A1 (fr) | 2015-09-02 | 2017-03-09 | The Regents Of The University Of California | Ligands her3 et utilisations de ceux-ci |
| WO2017062751A1 (fr) | 2015-10-08 | 2017-04-13 | The Regents Of The University Of California | Composés et méthodes permettant de favoriser la résistance au stress |
| WO2017066705A1 (fr) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Composés, compositions et méthodes d'utilisation contre des granules de stress |
| WO2017161028A1 (fr) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation |
| JP7179735B2 (ja) | 2016-09-28 | 2022-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重合性液晶材料および重合された液晶膜 |
| US10934261B2 (en) | 2016-09-28 | 2021-03-02 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| WO2018161033A1 (fr) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Inhibiteurs ire1-alpha à petites molécules |
| US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
| WO2018202681A1 (fr) | 2017-05-04 | 2018-11-08 | Bayer Cropscience Aktiengesellschaft | Utilisation de benzènes disubstitués pour lutter contre des organismes nuisibles résistants aux insecticides |
| JP2019015998A (ja) | 2017-07-03 | 2019-01-31 | 東芝テック株式会社 | 情報処理装置およびプログラム |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2019018119A1 (fr) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | Méthodes de traitement de l'épilepsie et d'affections associées à kcnti |
| CN111163766A (zh) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
| AU2019213694B2 (en) | 2018-01-30 | 2023-04-06 | Pi Industries Ltd. | Novel anthranilamides, their use as insecticide and processes for preparing the same. |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| WO2019207081A1 (fr) | 2018-04-27 | 2019-10-31 | Merck Patent Gmbh | Matériau de cristaux liquides polymérisables et film de cristaux liquides polymérisés |
| WO2019206925A1 (fr) | 2018-04-27 | 2019-10-31 | Merck Patent Gmbh | Matériau cristallin liquide polymérisable et film cristallin liquide polymérisé |
| WO2019241787A1 (fr) | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Nouveaux inhibiteurs cycliques de la gmp-amp synthase (cgaz) et leur procédé d'utilisation |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| US12698259B2 (en) | 2018-10-15 | 2026-08-04 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof |
| US12098117B2 (en) | 2018-12-11 | 2024-09-24 | Duke University | Compositions and methods for the treatment of cancer |
| WO2020139748A1 (fr) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Méthodes de traitement de maladies intestinales inflammatoires ciblant la ripk2 |
| WO2020146612A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters et carbamates utilisés en tant que modulateurs de canaux sodiques |
| WO2020146682A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides utilisés en tant que modulateurs de canaux sodiques |
| JP7534306B2 (ja) | 2019-01-22 | 2024-08-14 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 液晶ポリマーフィルムの製造方法 |
| CA3127590A1 (fr) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Activateurs de la mitofusine et leurs procedes d'utilisation |
| WO2020176763A1 (fr) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8 |
| JP2022525186A (ja) | 2019-03-15 | 2022-05-11 | ザ ジェネラル ホスピタル コーポレイション | Tead転写因子新規小分子阻害剤 |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2020219867A1 (fr) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur |
| WO2020221677A1 (fr) | 2019-04-30 | 2020-11-05 | Merck Patent Gmbh | Mésogènes réactifs |
| US20220324880A1 (en) | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
-
2018
- 2018-07-11 AU AU2018300150A patent/AU2018300150A1/en not_active Abandoned
- 2018-07-11 ES ES18746526T patent/ES3008911T3/es active Active
- 2018-07-11 MA MA049566A patent/MA49566A/fr unknown
- 2018-07-11 WO PCT/US2018/041649 patent/WO2019014352A1/fr not_active Ceased
- 2018-07-11 CA CA3069720A patent/CA3069720A1/fr not_active Abandoned
- 2018-07-11 UY UY0001037806A patent/UY37806A/es not_active Application Discontinuation
- 2018-07-11 CN CN201880058540.1A patent/CN111065383A/zh active Pending
- 2018-07-11 BR BR112020000553-3A patent/BR112020000553A2/pt not_active Application Discontinuation
- 2018-07-11 TN TNP/2020/000001A patent/TN2020000001A1/en unknown
- 2018-07-11 KR KR1020207003933A patent/KR20200026987A/ko not_active Withdrawn
- 2018-07-11 SG SG11202000230VA patent/SG11202000230VA/en unknown
- 2018-07-11 PE PE2020000022A patent/PE20201164A1/es unknown
- 2018-07-11 CR CR20200064A patent/CR20200064A/es unknown
- 2018-07-11 TW TW107123989A patent/TW201920081A/zh unknown
- 2018-07-11 EP EP18746526.5A patent/EP3651752B1/fr active Active
- 2018-07-11 JP JP2020501369A patent/JP7277431B2/ja active Active
- 2018-07-11 US US16/032,799 patent/US10647661B2/en active Active
-
2020
- 2020-01-05 JO JOP/2020/0001A patent/JOP20200001A1/ar unknown
- 2020-01-08 CO CONC2020/0000145A patent/CO2020000145A2/es unknown
- 2020-01-08 DO DO2020000004A patent/DOP2020000004A/es unknown
- 2020-01-08 PH PH12020500066A patent/PH12020500066A1/en unknown
- 2020-01-09 IL IL271948A patent/IL271948A/en unknown
- 2020-01-10 CL CL2020000075A patent/CL2020000075A1/es unknown
- 2020-01-15 EC ECSENADI20203147A patent/ECSP20003147A/es unknown
- 2020-03-19 US US16/824,255 patent/US11603351B2/en active Active
-
2022
- 2022-12-13 US US18/065,208 patent/US12281057B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020000075A1 (es) | 2020-07-31 |
| EP3651752C0 (fr) | 2024-11-20 |
| US12281057B2 (en) | 2025-04-22 |
| ECSP20003147A (es) | 2020-02-28 |
| JP2020526561A (ja) | 2020-08-31 |
| CN111065383A (zh) | 2020-04-24 |
| SG11202000230VA (en) | 2020-02-27 |
| US20190016671A1 (en) | 2019-01-17 |
| US11603351B2 (en) | 2023-03-14 |
| AU2018300150A1 (en) | 2020-01-30 |
| PH12020500066A1 (en) | 2020-09-28 |
| EP3651752B1 (fr) | 2024-11-20 |
| PE20201164A1 (es) | 2020-10-28 |
| US10647661B2 (en) | 2020-05-12 |
| CA3069720A1 (fr) | 2019-01-17 |
| CO2020000145A2 (es) | 2020-01-17 |
| BR112020000553A2 (pt) | 2020-07-21 |
| US20210094906A1 (en) | 2021-04-01 |
| UY37806A (es) | 2020-01-31 |
| WO2019014352A1 (fr) | 2019-01-17 |
| KR20200026987A (ko) | 2020-03-11 |
| EP3651752A1 (fr) | 2020-05-20 |
| IL271948A (en) | 2020-02-27 |
| JOP20200001A1 (ar) | 2022-10-30 |
| DOP2020000004A (es) | 2020-07-15 |
| US20230286907A1 (en) | 2023-09-14 |
| TW201920081A (zh) | 2019-06-01 |
| ES3008911T3 (en) | 2025-03-25 |
| CR20200064A (es) | 2020-08-03 |
| JP7277431B2 (ja) | 2023-05-19 |
| TN2020000001A1 (en) | 2021-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA48803A (fr) | Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| ME03574B (fr) | Composés hétéroaryle utiles en tant qu'inhibiteurs de l'enzyme d'activation sumo | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux |